It was reported that the pharmacological inhibition of HIF-2α in PAH reduces hypertrophy, right ventricular systolic pressure, fibrosis, and pulmonary vascular remodeling; prevents RHF; and favors survival [31]. This evidence concerns the gene EPAS1 and pulmonary arterial hypertension.